CollPlant announced that Jonathan M.N. Rigby has been appointed as Chairman of the Board of Directors effective immediately. Mr. Rigby brings to CollPlant over 28 years of experience in the pharmaceutical, biopharmaceutical, medical device and drug delivery industries. Mr. Rigby has served as the President, CEO and a member of the Board of Directors of SteadyMed Ltd. Mr. Rigby led SteadyMed through its IPO in 2015 and subsequent sale to United Therapeutics in August 2018. He continues to serve as the President & CEO of SteadyMed. Since March 2016, Mr. Rigby has served on the Board of Directors of Xeris Pharmaceuticals and has been instrumental in the growth of the company and its subsequent IPO in mid 2018. Mr. Rigby succeeds Mr. Tsur, who served as Chairman of the Board since the beginning of 2018, during which time CollPlant made significant business progress, including entering into its first strategic licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.